Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quote | Spero Therapeutics Inc. (NASDAQ:SPRO)
Last: | $1.41 |
---|---|
Change Percent: | 0.69% |
Open: | $1.43 |
Close: | $1.41 |
High: | $1.4396 |
Low: | $1.4 |
Volume: | 43,369 |
Last Trade Date Time: | 07/30/2024 03:00:00 am |
News | Spero Therapeutics Inc. (NASDAQ:SPRO)
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced th...
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced t...
Message Board Posts | Spero Therapeutics Inc. (NASDAQ:SPRO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $SPRO News Article - Spero Therapeutics to Present Data at the 33rd European Congress o | whytestocks | investorshangout | 04/14/2023 12:20:48 PM |
znewcar1: $SPRO ML1.35 RL1.41 Looking bullish here! hold1.4? | znewcar1 | investorshangout | 04/03/2023 2:46:00 PM |
Urinary tract infection drug,$66m reviewed up to | 81vette | investorshub | 03/31/2023 5:44:27 PM |
Pfizer paid $5m of $40 and $80m total | 81vette | investorshub | 03/31/2023 5:37:09 PM |
Look at the candle on this chart 6 | 81vette | investorshub | 03/31/2023 5:30:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Spero Therapeutics Inc. Company Name:
SPRO Stock Symbol:
NASDAQ Market:
Spero Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced th...
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced t...
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...